Search
for
Sort by
Research 91–120 of 1000+
- Sulfatase inhibitors: a patent review
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
- Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats
- Paracrine Secreted Frizzled-Related Protein 4 Inhibits Melanocytes Differentiation in Hair Follicle
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- iNOS inhibits hair regeneration in obese diabetic (ob/ob) mice
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Leydig Cell Hyperplasia and Adenomas in Mice Treated with Finasteride, a 5α-Reductase Inhibitor: A Possible Mechanism
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
- Purified Vitexin Compound 1 Inhibits UVA-Induced Cellular Senescence in Human Dermal Fibroblasts by Binding Mitogen-Activated Protein Kinase 1
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Maternal androgen excess inhibits fetal cardiomyocytes proliferation through RB-mediated cell cycle arrest and induces cardiac hypertrophy in adulthood
- [4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs
- Fibroblast growth factor 5-short (FGF5s) inhibits the activity of FGF5 in primary and secondary hair follicle dermal papilla cells of cashmere goats
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)